This study focuses on patients with Spinocerebellar Ataxia, specifically type SCA27B, which is a rare genetic condition affecting movement and balance due to problems in a part of the brain called the cerebellum. The study will test a medication called Fampridine, given as prolonged-release tablets, to see if it can help improve symptoms in people with this condition.

The main purpose of this research is to determine if taking Fampridine tablets twice daily for 12 weeks helps patients with SCA27B. During the study, some patients will receive Fampridine while others will receive placebo. The medication or placebo will be taken by mouth, with a maximum daily dose of 20 mg of Fampridine for those in the treatment group.

The study will last 16 weeks in total, including a 12-week treatment period followed by 4 weeks of observation after stopping the medication. Throughout the study, doctors will monitor various aspects of the participants’ movement abilities, balance, daily activities, and overall well-being. They will also check for any potential side effects through regular medical examinations and blood tests.